open-systems-pharmacology / cabozantinib-model

Cabozantinib PBPK

Cabozantinib-Model

Cabozantinib PBPK

Repository files

Within this repository we share whole body PBPK model of the TKI Cabozantinib with enterohepatic recirculation (EHC) and drug-drug-interaction (DDI) via CYP3A4 inducer. The model was developed using available pharmacokinetic studies. The model describes the EHC and the DDIs with Rifampin as CYP3A4 inducer.

For a detailed documentation of model development, quantitative model evaluation and sensitivity analysis, please refer to [1].

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model code is distributed under the GPLv2 License.

References

[1] Gerner, B.; Scherf-Clavel, O. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment. Pharmaceutics 2021, 13(6), 778.

cabozantinib-model's Issues

Fix the project snapshot